Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.

Volume 5 (2008), Issue 2 (February)

1. Heparan sulfate-dependent ERK activation contributes to the overexpression of fibrotic proteins and enhanced contraction by scleroderma fibroblasts.
   Arthritis Rheum, 58(2): 577-585. [Abstract] [Full-text]
2. Neoadjuvant imatinib in a gastrointestinal stromal tumor of the rectum: Report of a case.
   Surg Today, 38(2): 174-7. [Abstract] [Full-text]
3. Sustained remissions and low rate of BCR-ABL resistance mutations with imatinib treatment chronic myelogenous leukemia in patients treated in late chronic phase: a 5-year follow up.
   Am J Hematol, 83(3): 178-84. [Abstract] [Full-text]
4. Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity.
   Ann Oncol, 19(2): 359-61. [Abstract] [Full-text]
5. Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy.
   Haematologica, 93(2): 287-90. [Abstract] [Full-text]
6. Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib.
   Haematologica, 93(2): 186-92. [Abstract] [Full-text]
7. I{kappa}B kinase {beta} inhibition induces cell death in Imatinib-resistant and T315I Dasatinib-resistant BCR-ABL+ cells.
   Mol Cancer Ther. [Abstract] [Full-text]
8. Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib.
   Haematologica, 93(2): 317-8. [Abstract] [Full-text]
9. Discovery and SAR of 1,3,4-thiadiazole derivatives as potent Abl tyrosine kinase inhibitors and cytodifferentiating agents.
   Bioorg Med Chem Lett, 18(3): 1207-11. [Abstract] [Full-text]
10. Targeting the Epidermal Growth Factor Receptor in High-Grade Astrocytomas.
    Curr Treat Options Oncol. [Abstract] [Full-text]
11. New developments in multitargeted therapy for patients with solid tumours.
    Cancer Treat Rev, 34(1): 37-48. [Abstract] [Full-text]
12. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?
    Cancer, 112(4): 837-45. [Abstract] [Full-text]
13. Gene expression analysis of BCR/ABL1-dependent transcriptional response reveals enrichment for genes involved in negative feedback regulation.
    Genes Chromosomes Cancer, 47(4): 267-75. [Abstract] [Full-text]
14. A 17 year-old man with an exon 11 mutation of CD-117 causing a gastrointestinal stromal tumor.
    Cancer Invest, 26(2): 182-4. [Abstract] [Full-text]
15. In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib.
    Blood, 111(4): 2378-81. [Abstract] [Full-text]
16. Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib.
    Blood, 111(4): 2200-10. [Abstract] [Full-text]
17. Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606.
    Blood, 111(4): 2329-38. [Abstract] [Full-text]
18. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.
    Blood, 111(4): 1834-9. [Abstract] [Full-text]
19. Fusion of PRKG2 and SPTBN1 to the platelet-derived growth factor receptor beta gene (PDGFRB) in imatinib-responsive atypical myeloproliferative disorders.
    Cancer Genet Cytogenet, 181(1): 46-51. [Abstract] [Full-text]
20. Development and validation of GC-MS method for the determination of methyl methanesulfonate and ethyl methanesulfonate in imatinib mesylate.
    J Pharm Biomed Anal, 46(4): 780-3. [Abstract] [Full-text]
21. Clinical relevance of the homologous recombination machinery in cancer therapy.
    Cancer Sci, 99(2): 187-94. [Abstract] [Full-text]
22. Roles for deregulated receptor tyrosine kinases and their downstream signaling molecules in hematologic malignancies.
    Cancer Sci, 99(3): 479-85. [Abstract] [Full-text]
23. Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate.
    Leuk Res, 32(2): 255-261. [Abstract] [Full-text]
24. Rituximab associated to imatinib for coexisting therapy-related chronic myeloid leukaemia and relapsed non-Hodgkin lymphoma.
    Leuk Res, 32(2): 353-355. [Abstract] [Full-text]
25. All-trans-retinoic acid enhances apoptosis induction by tyrosine kinase inhibitors in the eosinophilic leukemia-derived EoL-1 cell line.
    Leuk Res, 32(2): 343-346. [Abstract] [Full-text]
26. Clinical implications of mutational analysis in gastrointestinal stromal tumours.
    Br J Cancer, 98(4): 684-8. [Abstract] [Full-text]
27. Surgical resection of residual disease in initially inoperable imatinib-resistant/intolerant gastrointestinal stromal tumor treated with sunitinib.
    Eur J Surg Oncol. [Abstract] [Full-text]
28. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
    Leuk Res, 32(4): 643-9. [Abstract] [Full-text]
29. A case of Philadelphia-chromosome positive chronic idiopathic myelofibrosis.
    Leuk Res, 32(4): 665-7. [Abstract] [Full-text]
30. In vitro biotransformation of imatinib by the tumor expressed CYP1A1 and CYP1B1.
    Biopharm Drug Dispos, 29(2): 103-18. [Abstract] [Full-text]
31. Imatinib mesylate in early chronic phase chronic myeloid leukemia: Experience from a developing country.
    Leuk Lymphoma, 49(3): 554-8. [Abstract] [Full-text]
32. Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products.
    Leuk Lymphoma, 49(3): 531-7. [Abstract] [Full-text]
33. Trisomy 6 in a CML patient receiving imatinib mesylate therapy.
    Leuk Res. [Abstract] [Full-text]
34. Gastrointestinal stromal tumors and leiomyosarcomas.
    J Surg Oncol, 97(4): 350-9. [Abstract] [Full-text]
35. Long-term imatinib therapy promotes bone formation in CML patients.
    Blood, 111(5): 2538-47. [Abstract] [Full-text]
36. Complete molecular response of e6a2 BCR-ABL-positive acute myeloid leukemia to imatinib then dasatinib.
    Blood, 111(5): 2896-8. [Abstract] [Full-text]
37. BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors.
    Blood, 111(5): 2843-53. [Abstract] [Full-text]
38. BCR-ABL1 mediates up-regulation of Fyn in chronic myelogenous leukemia.
    Blood, 111(5): 2904-8. [Abstract] [Full-text]
39. Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia.
    Blood, 111(5): 2581-8. [Abstract] [Full-text]
40. Classifying protein kinase structures guides use of ligand-selectivity profiles to predict inactive conformations: structure of lck/imatinib complex.
    Proteins, 70(4): 1451-60. [Abstract] [Full-text]
41. Oral mucosa lesions in hypereosinophilic syndrome--an update.
    Oral Dis, 14(2): 115-22. [Abstract] [Full-text]
42. Mathematical Modeling of Genesis and Treatment of Chronic Myeloid Leukemia.
    Cells Tissues Organs. [Abstract] [Full-text]
43. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCELtrade mark), a multi-targeted kinase inhibitor.
    Cancer Chemother Pharmacol. [Abstract] [Full-text]
44. Monitoring minimal residual disease in patients with chronic myeloid leukemia after treatment with tyrosine kinase inhibitors.
    Curr Opin Hematol, 15(2): 134-9. [Abstract] [Full-text]
45. Who with chronic myelogenous leukemia to transplant in the era of tyrosine kinase inhibitors?
    Curr Opin Hematol, 15(2): 127-33. [Abstract] [Full-text]
46. An intron-derived insertion/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy.
    J Mol Diagn, 10(2): 177-80. [Abstract] [Full-text]
47. Long-term remission with imatinib mesylate in Philadelphia chromosome-positive AML presenting as primary extramedullary myeloid sarcoma.
    Leuk Res. [Abstract] [Full-text]

© 2004-2008 Glivec Research Today. All Rights Reserved.